KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Non-Current Debt (2016 - 2026)

Bristol Myers Squibb has reported Non-Current Debt over the past 18 years, most recently at $42.2 billion for Q1 2026.

  • Quarterly Non-Current Debt fell 8.68% to $42.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $42.2 billion through Mar 2026, down 8.68% year-over-year, with the annual reading at $42.8 billion for FY2025, 9.98% down from the prior year.
  • Non-Current Debt was $42.2 billion for Q1 2026 at Bristol Myers Squibb, down from $42.8 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $49.5 billion in Q1 2024 and troughed at $32.1 billion in Q3 2023.
  • The 5-year median for Non-Current Debt is $42.2 billion (2026), against an average of $41.2 billion.
  • Year-over-year, Non-Current Debt fell 15.85% in 2022 and then surged 51.46% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $35.1 billion in 2022, then rose by 4.56% to $36.7 billion in 2023, then grew by 29.87% to $47.6 billion in 2024, then fell by 9.98% to $42.8 billion in 2025, then fell by 1.63% to $42.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Non-Current Debt are $42.2 billion (Q1 2026), $42.8 billion (Q4 2025), and $44.5 billion (Q3 2025).